Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
PMID 16399907
2001 Feb;174(2):11823
Phase 3 clinical trials are underway, with promising results beyond even weight loss
Less Commonly Reported Effects Headache, light-headedness, vivid dreams (often attributed to BPC-157), and brief appetite changes are reported less frequently
Unlike its cousin afamelanotide, also known as Melanotan I which has limited, regulated medical use MT-2 has no approved use
This is partly because it helps lower blood pressure, improves cholesterol levels, and reduces inflammation
US$ 20.15
US$ 24.13
US$ 26.30
US$ 23.14
